7 results
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Glucagon-like peptide 1; normally ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Resistant Tuberculosis ... are contacts of infectious ... MultiDrugResistant #Tuberculosis ... #MDRTB #management ... antimicrobials #regimens #pharmacology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors - Normal ... This drug class ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucoadhesive buccal tablet ... chew, or crush tablet ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... Please refer to the table ... Mycobacterium #Tuberculosis ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
order for the drug ... to remain stable ... to ensure the drug ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
necessary based on drug-drug ... please refer to Table ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology